Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre

BACKGROUND: Patients with hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT), especially type Vp-4, usually have a poor prognosis. However, the vast majority of Phase III clinical trials exclude this population based on the inclusion criteria. Lenvatinib plus a PD-1 inhibitor has...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guangxin, Zhao, Ying, Li, Keren, Yang, Shizhong, Xiang, Canhong, Song, Jiyong, Yang, Yanmei, Li, Gong, Dong, Jiahong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642359/
https://www.ncbi.nlm.nih.gov/pubmed/37965075
http://dx.doi.org/10.2147/JHC.S432542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642359/
https://www.ncbi.nlm.nih.gov/pubmed/37965075
http://dx.doi.org/10.2147/JHC.S432542

Ejemplares similares